Figure 5 provides a summary of the sample-weighted mean detection rates of 68Ga-PSMA-11, 18F-DCFPyL and 18F-flotufolastat among patients with biochemical recurrence of prostate cancer to illustrate the impact of low PSA level and prior treatment. This evidence concerns the gene FOLH1 and prostate cancer.